Matinas BioPharma Holdings (STU:6LJ) ROCE % : -117.98% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Matinas BioPharma Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Matinas BioPharma Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was -117.98%.

Matinas BioPharma Holdings ROCE % Historical Data

The historical data trend for Matinas BioPharma Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Matinas BioPharma Holdings ROCE % Chart

Matinas BioPharma Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-70.28

-44.80

-41.37

-52.35

-74.03

Matinas BioPharma Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-57.78	-72.21	-85.31	-94.90	-117.98

Matinas BioPharma Holdings ROCE % Calculation

Matinas BioPharma Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-21.793	/	( ( (42.309 - 4.046)	+	(23.02 - 2.404) )	/ 2 )
	=	-21.793	/	( (38.263	+	20.616)	/ 2 )
	=	-21.793	/	29.4395
	=	-74.03 %

Matinas BioPharma Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-21.72	/	( ( (23.02 - 2.404)	+	(18.041 - 1.838) )	/ 2 )
	=	-21.72	/	( ( 20.616	+	16.203 )	/ 2 )
	=	-21.72	/	18.4095
	=	-117.98 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Matinas BioPharma Holdings (STU:6LJ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Matinas BioPharma Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Matinas BioPharma Holdings (STU:6LJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (STU:6LJ) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MTNB:USA

Address

1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921

Website

https://www.matinasbiopharma.com

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.

Matinas BioPharma Holdings (STU:6LJ) Headlines

No Headlines